NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today provided its outlook for 2026 ahead of attendance at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco, California, on January 12 – 15, 2026. Dr Srinivas Rao, Co-Founder and Chief Executive Officer of AtaiBeckley, said: ...

Core Argument - The mental health field should move beyond diagnosis and consider the individual's context, history, and societal influences [6][11][18] - Mental health diagnoses are valuable tools but should not overshadow the individual's unique experiences and the broader societal factors contributing to their distress [7][8] - Systemic oppression, societal expectations, and cultural realities significantly impact mental health, particularly for marginalized communities [5][12][13] Societal Impact on Mental Health - Societal structures and policies, such as discrimination and lack of inclusive education, contribute to mental health challenges [3][12][13] - The mental health field needs to understand the intersection of societal structures and individual experiences to provide effective treatment [14] - Stigma associated with mental health labels can perpetuate misunderstanding and reduce individuals to a set of symptoms [10] Holistic Approach to Mental Health - Mental health professionals, educators, families, and society should see the whole person, considering their context, culture, and history [11][18] - A compassionate and effective approach to mental health involves honoring the fullness of an individual's experience and recognizing their strengths [16][17] - Encourages a shift from asking "what is wrong with you" to "what happened to you" to understand the individual's pain and help them reclaim their strengths [19] Resilience and Empowerment - Despite challenges, individuals and communities demonstrate resilience in the face of adversity [14][15] - Empowering individuals by exploring their identity, community, and history can help them overcome mental health challenges [15][16] - Recognizing and honoring the strengths of individuals, such as creativity and meticulousness, can be an effective approach to mental health care [17]

HOUSTON, TX, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL) is pleased to invite investors to a webinar on December 4, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Nexalin’s CEO Mark White, who will provide an inside look at Nexalin’s game-changing approach to mental healthcare through its proprietary, non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology. White will detail the Company’s growin ...

Summary of BrainsWay 2025 Investor Day Company Overview - **Company**: BrainsWay (NasdaqGM:BWAY) - **Industry**: Mental Health Technology - **Core Product**: Noninvasive brain stimulation technology, specifically Deep Transcranial Magnetic Stimulation (TMS) for treating major mental health conditions [6][5][3] Key Financial Highlights - **Q3 Revenue**: $13.5 million, up 29% year-over-year [7] - **Gross Margin**: 75% [7] - **Adjusted EBITDA**: $2 million, up 81% [7] - **Net Profit**: $1.6 million, up 137% [7] - **Remaining Performance Obligation**: $65 million, up 37% year-over-year [8] - **Systems Shipped**: 90 systems, up 43% [8] - **Customer Retention Rate**: 93% [12] - **Cash Position**: $71 million, no debts [13] Business Model Transition - Transition from a one-time sale model to a recurring revenue model, with recurring revenue growing 34% year-over-year [13][14] - Shift towards multiyear leases, with 70% of new deals being multiyear [9] - Expected revenue growth from $10 million in 2023 to $18.4 million in 2025 for recurring revenue [14] Clinical and Regulatory Developments - **FDA Clearance**: Accelerated protocol for Major Depressive Disorder (MDD) [9] - **NIH Grant**: $2.5 million grant for Deep TMS for alcohol use disorder [10] - **New Clinical Indications**: Expansion into PTSD, addiction, and cognitive decline [18] Strategic Partnerships and Investments - Four strategic minority investments in mental health clinics to expand access and utilization [11][23] - Partnership with Valo Equity Partners, a $20 billion technology-focused investment fund, to scale operations [20] Market Opportunity and Growth Strategy - **Total Addressable Market (TAM)**: Significant unmet need in mental health, with millions suffering from PTSD, depression, and anxiety [35] - Plans to expand into new care settings, including home use and international markets [24][25] - Development of a connected mental health ecosystem, integrating various treatment modalities [25] Future Milestones - Targeting five enterprise deployments before 2025 [28] - Launch of the Nuuly home-use device for MDD [29] - Continued focus on expanding the neurology portfolio and global presence [30] Competitive Landscape - BrainsWay is positioned as a leader in TMS technology, with a focus on innovative treatment protocols that improve patient outcomes [6][63] - The company aims to differentiate itself through its unique Deep TMS technology and integrated care model [64] Conclusion - BrainsWay is at a pivotal point with strong financial performance, a robust growth strategy, and significant market opportunities in the mental health sector. The company is well-positioned to capitalize on the increasing demand for effective mental health treatments and innovative care delivery models [31][32]

Core Insights - Atai Beckley NV (NASDAQ:ATAI) is highlighted as a promising investment opportunity due to its positive clinical developments and strong financial position [1][2]. Financial Performance - In the third quarter, Atai Beckley reported revenue of $749,000, significantly exceeding expectations of $55,560 [2]. - The company has a cash runway extending to 2029, bolstered by recent equity financing [1]. Clinical Developments - Positive Phase 2b results for BPL-003 in treatment-resistant depression showed remission and response rates of 67% and 81% respectively by day 57 [3]. - BPL-003 has received FDA's Breakthrough Therapy designation, marking a significant milestone in its development [2]. Drug Profile and Comparison - BPL-003 demonstrated a favorable safety profile and patients were discharged within two hours, indicating its potential advantages over Spravato [4]. - The choice of an 8mg dose for Phase 3 trials is expected to strengthen confidence in the drug's efficacy [1]. Pipeline and Future Prospects - The company is advancing its pipeline with full enrollment in the EMP-01 Phase 2a study for social anxiety and expanding trial sites for VLS-01 [5]. - Atai Beckley secured a NIDA grant to explore 5-HT2A/2C receptor agonists for opioid use disorder, indicating a commitment to innovation in mental health treatments [5][6].

Core Insights - Atai Beckley N.V. is a clinical-stage biopharmaceutical company focused on developing effective and rapid-acting mental health treatments [2] - The company was formed through the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited in November 2025 [2] - Key products in Atai Beckley's pipeline include BPL-003, VLS-01, and EMP-01, all of which are in Phase 2 clinical development targeting treatment-resistant depression and social anxiety disorder [2] Company Participation - Srinivas Rao, M.D., Ph.D., and Kevin Craig, M.D. will participate in the Jefferies Global Healthcare Conference in London [1] - The format will include a fireside chat and one-on-one investor meetings scheduled for November 20 at 11:30 A.M. GMT [1] - An archived replay of the event will be available on the company's website for up to 90 days [1]

Core Insights - AtaiBeckley has established itself as a global leader in transformative mental health therapies, particularly focusing on rapid-acting psychedelic treatments [2][3] - The FDA granted Breakthrough Therapy designation for BPL-003, indicating its potential to significantly improve treatment for patients with treatment-resistant depression (TRD) [3][4] - The company has made substantial progress in its clinical pipeline, including positive Phase 2a and Phase 2b data for BPL-003 and advancements in other therapies [2][3] Financial Performance - As of September 30, 2025, the company reported cash, cash equivalents, and short-term securities of $114.6 million, an increase from $72.3 million at the end of 2024, primarily due to $148.8 million in net proceeds from equity issuances [7][9] - The net loss for the three months ended September 30, 2025, was $61.1 million, compared to $26.3 million for the same period in 2024, with a significant portion attributed to non-cash expenses [12][18] - Research and development expenses increased to $14.7 million for the third quarter of 2025, up from $12.4 million in the prior year, reflecting higher costs associated with clinical programs [10][11] Clinical Developments - BPL-003, a mebufotenin nasal spray, has shown positive topline results in Phase 2b studies, demonstrating sustained antidepressant effects after a second dose [3][4] - The company completed enrollment in the Phase 2a trial of EMP-01 for social anxiety disorder and received a grant from NIDA to support the development of novel 5-HT2A/2C receptor agonists for opioid use disorder [3][8] - An End-of-Phase 2 meeting with the FDA is scheduled to discuss the Phase 3 clinical program for BPL-003, with guidance expected in the first quarter of 2026 [3][8] Corporate Updates - The strategic combination of atai Life Sciences and Beckley Psytech has created AtaiBeckley, enhancing its position in the mental health treatment landscape [2][13] - The company appointed Scott Braunstein, M.D., as Vice Chairman and Lead Independent Director, bringing extensive experience in the biopharmaceutical industry [8] - AtaiBeckley plans to redomicile to the U.S. by the end of 2025, pending satisfaction of closing conditions [8]